The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.
 
Edwin R. Parra
No Relationships to Disclose
 
Dzifa Yawa Duose
Honoraria - Chrysalis Biomedical Advisors
Patents, Royalties, Other Intellectual Property - patent
 
Jiexin Zhang
No Relationships to Disclose
 
Mary Weber Redman
No Relationships to Disclose
 
Rossana Lazcano Segura
No Relationships to Disclose
 
Mario L. Marques-Piubelli
No Relationships to Disclose
 
Caddie Laberiano Fernandez
No Relationships to Disclose
 
BaiLi Zhang
No Relationships to Disclose
 
James Lindsay
No Relationships to Disclose
 
Radim Moravec
No Relationships to Disclose
 
Kasthuri Kannan
No Relationships to Disclose
 
Rajyalakshmi Luthra
Patents, Royalties, Other Intellectual Property - Patent
 
Gheath Alatrash
No Relationships to Disclose
 
Roy S. Herbst
Leadership - Immunocore; Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Bayer; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; Candel Therapeutics; Checkpoint Therapeutics; Cybrexa Therapeutics; DynamiCure Biotechnology; eFFECTOR Therapeutics; EMD Serono; Foundation Medicine; Genentech/Roche; Genmab; Gilead/Forty Seven; Halozyme; Heat Biologics; HiberCell; I-Mab; Immune-Onc Therapeutics; Infinity Pharmaceuticals; Johnson and Johnson; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Ocean Biomedical; OncoCyte; Oncternal Therapeutics; Pfizer; Refactor Health; Ribon Therapeutics; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; STCube Pharmaceuticals Inc.; Symphogen; Takeda; TESARO; Tocagen; Ventana Medical Systems; WindMIL; Xencor
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Asuragen; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Lilly; Flame Biosciences; Flame Biosciences; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Merck; MSD Oncology; Novartis; OncoCyte; Pfizer; Sanofi
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Merck; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Adaptive Biotechnologies (Inst); Akoya Biosciences (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sanofi (Inst); Takeda (Inst)
 
Scott N. Gettinger
Research Funding - ARIAD/Takeda (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck (Inst); NextCure (Inst)
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Bayer; BMSi; Boehringer Ingelheim; Daichi; Genentech/Roche; Johnson and Johnson; Merck; Mirati Therapeutics; neuvogen; Novartis; Novocure; ORCIC; Regeneron; Sanofi; Turning Point Therapeutics
 
J. Jack Lee
Honoraria - AstraZeneca; AstraZeneca
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Geneplus; innovent biologics; Innovent Biologics; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Capital Medical University; Geneplus; Johnson & Johnson/Janssen; Novartis
Research Funding - Merck; Novartis
Travel, Accommodations, Expenses - innovent biologics; Zhejiang Cancer Hospital
 
Cara L. Haymaker
Stock and Other Ownership Interests - Briacell
Consulting or Advisory Role - Nanobiotix
Research Funding - Dragonfly Therapeutics (Inst); Idera (Inst); Iovance Biotherapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent Appl No. 62/977, 672 (Inst)